According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “
Separately, ValuEngine raised shares of INDIVIOR PLC/S from a “strong sell” rating to a “sell” rating in a research report on Wednesday, April 10th.
OTCMKTS:INVVY opened at $2.83 on Wednesday. INDIVIOR PLC/S has a 12 month low of $1.98 and a 12 month high of $33.83. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.62 and a quick ratio of 1.53. The stock has a market capitalization of $409.31 million, a PE ratio of 1.57 and a beta of 0.30.
INDIVIOR PLC/S (OTCMKTS:INVVY) last posted its earnings results on Thursday, February 14th. The company reported $0.45 EPS for the quarter. INDIVIOR PLC/S had a net margin of 27.49% and a negative return on equity of 3,640.00%. The firm had revenue of $236.00 million during the quarter. As a group, research analysts forecast that INDIVIOR PLC/S will post -0.29 earnings per share for the current year.
INDIVIOR PLC/S Company Profile
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Read More: Balanced Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.